Last reviewed · How we verify
Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis (ASEPTIC)
A multicentre, interventional, double-blind, placebo-controlled, parallel-arm, phase 3, randomised controlled trial to evaluate the use of co-trimoxazole as primary prophylaxis for spontaneous bacterial peritonitis to improve overall survival
Details
| Lead sponsor | University College, London |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 442 |
| Start date | 2019-06-30 |
| Completion | 2025-10 |
Conditions
- Spontaneous Bacterial Peritonitis
Interventions
- Co-Trimoxazole 960Mg Dispersible Tablet
- Placebo oral tablet
Primary outcomes
- Overall Survival — The maximum possible period of follow up will be 48 months (assuming a recruitment period of 30 months and 18 months treatment period for final patient recruited)
Overall Survival
Countries
United Kingdom